Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP forum goes gratis

This article was originally published in The Tan Sheet

Executive Summary

The Pharmacopeial Forum becomes a free online resource starting in January, the U.S. Pharmacopeia says Sept. 8, allowing "greater participation in the standards-setting process for drugs, excipients and dietary supplements." PF is the nonprofit group's journal for public comment, giving manufacturers, regulators and other stakeholders a chance to provide feedback on proposed standards before they become official in USP's National Formulary. The May-June issue of PF sought comments on standards for bacopa monnieri, garcinia gummi-gutta and other Indian botanicals used in supplements and traditional medicines (1"The Tan Sheet" May 10, 2010, In Brief)

You may also be interested in...



USP standardizes Indian botanicals

The U.S. and Indian pharmacopeias jointly propose standards for the identity, strength, quality and purity of four botanical articles in multiple forms used in U.S. dietary supplements and Indian traditional medicines. Monographs for the botanicals bacopa monnieri, garcinia gummi-gutta, garcinia indica and plectranthus barbatus are in the May-June issue of Pharmacopeial Forum, USP said May 5. The Rockville, Md.-based organization seeks comments on the standards before they are finalized. USP will publish official monograph standards for the botanicals ashwagandha root, andrograpahis aerial parts and boswellia serrata in February 2011, USP said

AbbVie/Allergan Merger Edges Closer To FTC Clearance

AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.

Another Sterilization Plant Closes For Upgrades; FDA Monitoring Situation For Device Shortage

The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.

Topics

UsernamePublicRestriction

Register

PS104502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel